Supplementary Table S6: Summary of anti-tumor activity and disease control rate according to RECIST and iRECIST (treated population)

	Escalation monotherapy		Escalation combination		Expansion combination	
	SAR441000 (*N*=21)		SAR441000 + cemiplimab (*N*=15)		SAR441000 + cemiplimab (*N*=41)	
Confirmed BOR (RECIST 1.1)						
CR, *n* (%)	0		0		0	
PR, *n* (%)	0		1 (6.7)		2 (4.9)	
SD of any duration, *n* (%)	4 (19.0)		3 (20.0)		10 (24.4)	
PD, *n* (%)	13 (61.9)		11 (73.3)		24 (58.5)	
NE* *n* (%)	4 (19.0)		0		5 (12.2)	
	RECIST 1.1	**iRECIST**	**RECIST 1.1**	**iRECIST**	**RECIST 1.1**	**iRECIST**
ORR, 90% CI	–	– 0.0–13.3	1 (6.7) 0.3–27.9	2 (13.3) 2.4–36.3	2 (4.9) 0.9–14.6	2 (4.9) 0.9–14.6
DCR, 90% CI	4 (19.0) 6.8–38.4	4 (19.0) 6.8–38.4	4 (26.7) 9.7–51.1	5 (33.3) 14.2–57.7	12 (29.3) 17.8–43.1	14 (34.1) 22.0–48.1
Median PFS, months	1.7 1.42–1.95	2.9 1.69–7.47	2.0 1.02–2.12	8.3 3.04–NR	2.1 1.95–2.28	5.2 2.84–8.40
Median DoR, months	-	-	-	19.2 17.32–NR	8.9 4.99–NR	8.9 4.99–NR

*Patients discontinued from the study prior to efficacy evaluation.

BOR, best overall response; CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; iRECIST, immune response evaluation criteria in solid tumors; *N*, number of patients; NE, not evaluable; NR, not reached; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease.